Biogen and Sage Therapeutics Share Update on FDA Advisory Committee for Zuranolone | Biogen
Sage Therapeutics Gets $1.53B From Biogen in a Collaboration Deal
Sage and Biogen plan for zuranolone NDA filing
Sage/Biogen Announce Positive Results in Ph. 3 CORAL Depression Drug Trial - YouTube
Biogen makes risky bet on trial depression drug - The Boston Globe
Sage Therapeutics, Biogen Start Rolling Submission For Zuranolone In Major Depressive Disorder
Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology (ACNP) Congress | Business Wire
Sage Therapeutics Archives - Drug Discovery and Development
Sage-Biogen drug improves symptoms in postpartum depression study | Reuters
Biogen, Sage win FDA priority review for depression therapy (NASDAQ:BIIB) | Seeking Alpha
Biogen and Sage get August PDUFA date for oral depression drug
Neurology Drug Study Does Little for Sage Therapeutics, or Its Partner Biogen | Barron's
Sage Therapeutics y Biogen presentan nuevos datos de eficacia y seguridad de su tratamiento para depresión mayor y postparto - enFarma
Sage-Biogen drug improves symptoms in postpartum depression study, Health News, ET HealthWorld
Biogen Bets $1.5 Billion on Sage Therapeutics' Drug for Depressive Disorders | BioSpace
Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application for Zuranolone to the FDA in 2022
Biogen signs $1.5bn depression drug deal with Sage Therapeutics
NDA for Biogen-Sage's Zuranolone Accepted by FDA, Marking Another Step Forward in Depression Drug Development - GeneOnline News
Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD-CliniExpert
Biogen Gives Sage Therapeutics $1.5 Billion In Deal To Develop Depression And Tremor Treatments | The Healthcare Technology Report.
Biogen, Sage Therapeutics get USFDA priority review for depression drug Zuranolone
Should You Buy Sage Stock After the Biogen Investment? | The Motley Fool
Sage, Biogen show good results on zuranolone phase 3 depression trial - MedWorks Media
Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology (ACNP) Congress | Business Wire
Sage/Biogen Zuranolone Study Shows More Efficacy, But Higher Toxicity :: Scrip
FDA accepts NDA and grants priority review of Zuranolone from Sage Therapeutics, Biogen - Express Pharma
